Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine and CBASP in Chronic Depression
NCT06410599Phase 2Recruiting
- Sponsor
- University Hospital Tübingen
- Start
- Apr 2024
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ketamine in major depressive disorder (MDD) (3 arms), sponsored by University Hospital Tübingen. Primary endpoint: Montgomery-Åsberg Depression Rating Scale at 3 months. Started Apr 2024; status: recruiting.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06410599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06410599.